153 related articles for article (PubMed ID: 26993518)
1. Validation of a two-tier grading system in an unselected, consecutive cohort of serous ovarian cancer patients.
Battista MJ; Cotarelo C; Almstedt K; Heimes AS; Makris GM; Weyer V; Schmidt M
Arch Gynecol Obstet; 2016 Sep; 294(3):599-606. PubMed ID: 26993518
[TBL] [Abstract][Full Text] [Related]
2. Grading ovarian serous carcinoma using a two-tier system.
Malpica A; Deavers MT; Lu K; Bodurka DC; Atkinson EN; Gershenson DM; Silva EG
Am J Surg Pathol; 2004 Apr; 28(4):496-504. PubMed ID: 15087669
[TBL] [Abstract][Full Text] [Related]
3. Reclassification of serous ovarian carcinoma by a 2-tier system: a Gynecologic Oncology Group Study.
Bodurka DC; Deavers MT; Tian C; Sun CC; Malpica A; Coleman RL; Lu KH; Sood AK; Birrer MJ; Ozols R; Baergen R; Emerson RE; Steinhoff M; Behmaram B; Rasty G; Gershenson DM
Cancer; 2012 Jun; 118(12):3087-94. PubMed ID: 22072418
[TBL] [Abstract][Full Text] [Related]
4. [Evaluation of two-tier grading system and significance of p53 protein over-expression in ovarian serous carcinoma].
Lin J; Du J; Zhang CY; Xie QT; Zhang B; Liu CR
Zhonghua Bing Li Xue Za Zhi; 2010 Oct; 39(10):655-60. PubMed ID: 21176529
[TBL] [Abstract][Full Text] [Related]
5. Testing of two binary grading systems for FIGO stage III serous carcinoma of the ovary and peritoneum.
Seidman JD; Horkayne-Szakaly I; Cosin JA; Ryu HS; Haiba M; Boice CR; Yemelyanova AV
Gynecol Oncol; 2006 Nov; 103(2):703-8. PubMed ID: 16828848
[TBL] [Abstract][Full Text] [Related]
6. Age is associated with prognosis in serous ovarian carcinoma.
Deng F; Xu X; Lv M; Ren B; Wang Y; Guo W; Feng J; Chen X
J Ovarian Res; 2017 Jun; 10(1):36. PubMed ID: 28606125
[TBL] [Abstract][Full Text] [Related]
7. International Federation of gynecology and obstetrics staging classification for cancer of the ovary, fallopian tube, and peritoneum: estimation of survival in patients with node-positive epithelial ovarian cancer.
Pereira A; Pérez-Medina T; Magrina JF; Magtibay PM; Rodríguez-Tapia A; Peregrin I; Mendizabal E; Ortiz-Quintana L
Int J Gynecol Cancer; 2015 Jan; 25(1):49-54. PubMed ID: 25405578
[TBL] [Abstract][Full Text] [Related]
8. High levels of pretreatment CA125 are associated to improved survival in high grade serous ovarian carcinoma.
Morales-Vásquez F; Pedernera E; Reynaga-Obregón J; López-Basave HN; Gómora MJ; Carlón E; Cárdenas S; Silva-Ayala R; Almaraz M; Méndez C
J Ovarian Res; 2016 Jul; 9(1):41. PubMed ID: 27388275
[TBL] [Abstract][Full Text] [Related]
9. A retrospective analysis of immunohistochemically determined IRF4 (interferon regulating factor 4) expression in a consecutive cohort of 114 ovarian cancer patients.
Heimes AS; Schmidt M; Jäkel J; Almstedt K; Gebhard S; Weyer-Eiberich V; Elger T; Krajnak S; Brenner W; Hasenburg A; Battista MJ
Arch Gynecol Obstet; 2019 Jan; 299(1):239-246. PubMed ID: 30357498
[TBL] [Abstract][Full Text] [Related]
10. Aldehyde dehydrogenase 1/epidermal growth factor receptor coexpression is characteristic of a highly aggressive, poor-prognosis subgroup of high-grade serous ovarian carcinoma.
Liebscher CA; Prinzler J; Sinn BV; Budczies J; Denkert C; Noske A; Sehouli J; Braicu EI; Dietel M; Darb-Esfahani S
Hum Pathol; 2013 Aug; 44(8):1465-71. PubMed ID: 23465277
[TBL] [Abstract][Full Text] [Related]
11. Is the two-tier ovarian serous carcinoma grading system potentially useful in stratifying uterine serous carcinoma? A large multi-institutional analysis.
Ahmed Q; Hussein Y; Hayek K; Bandyopadhyay S; Semaan A; Abdul-Karim F; Al-Wahab Z; Munkarah AR; Elshaikh MA; Alosh B; Nucci MR; Van de Vijver KK; Morris RT; Oliva E; Ali-Fehmi R
Gynecol Oncol; 2014 Feb; 132(2):372-6. PubMed ID: 24262874
[TBL] [Abstract][Full Text] [Related]
12. [Clinicopathologic study and immunohistochemistry comparison of Pax2, p53 and Ki-67 in low- and high-grade ovarian serous carcinomas].
Shen XX; Yu L; Bi R; Yang WT
Zhonghua Bing Li Xue Za Zhi; 2011 Aug; 40(8):511-6. PubMed ID: 22169637
[TBL] [Abstract][Full Text] [Related]
13. [Construction and utilization of the prognostic model of serous ovarian adenocarcinoma].
Yang R; Feng J; Fang XZ; Bai F; Cheng YX; Liu C; Zhu W; Li L
Zhonghua Fu Chan Ke Za Zhi; 2006 Jul; 41(7):459-63. PubMed ID: 17083811
[TBL] [Abstract][Full Text] [Related]
14. Lymph node metastases as only qualifier for stage IV serous ovarian cancer confers longer survival than other sites of distant disease - a Swedish Gynecologic Cancer Group (SweGCG) study.
Hjerpe E; Staf C; Dahm-Kähler P; Stålberg K; Bjurberg M; Holmberg E; Borgfeldt C; Tholander B; Hellman K; Kjølhede P; Högberg T; Rosenberg P; Åvall-Lundqvist E
Acta Oncol; 2018 Mar; 57(3):331-337. PubMed ID: 29130381
[TBL] [Abstract][Full Text] [Related]
15. Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer.
Xu X; Deng F; Lv M; Ren B; Guo W; Chen X
J Ovarian Res; 2016 Dec; 9(1):85. PubMed ID: 27912779
[TBL] [Abstract][Full Text] [Related]
16. Lymph Node Involvement Pattern and Survival Differences of FIGO IIIC and FIGO IIIA1 Ovarian Cancer Patients After Primary Complete Tumor Debulking Surgery: A 10-Year Retrospective Analysis of the Tumor Bank Ovarian Cancer Network.
Gasimli K; Braicu EI; Nassir M; Richter R; Babayeva A; Chekerov R; Darb-Esfahani S; Sehouli J; Muallem MZ
Ann Surg Oncol; 2016 Apr; 23(4):1279-86. PubMed ID: 26832880
[TBL] [Abstract][Full Text] [Related]
17. Prognostic impact of HER3 based on protein and mRNA expression in high-grade serous ovarian carcinoma.
Unger U; Denkert C; Braicu I; Sehouli J; Dietel M; Loibl S; Darb-Esfahani S
Virchows Arch; 2017 Feb; 470(2):143-151. PubMed ID: 27913862
[TBL] [Abstract][Full Text] [Related]
18. The preoperative prognostic nutritional index is a predictive and prognostic factor of high-grade serous ovarian cancer.
Feng Z; Wen H; Ju X; Bi R; Chen X; Yang W; Wu X
BMC Cancer; 2018 Sep; 18(1):883. PubMed ID: 30200903
[TBL] [Abstract][Full Text] [Related]
19. HSP60 predicts survival in advanced serous ovarian cancer.
Hjerpe E; Egyhazi S; Carlson J; Stolt MF; Schedvins K; Johansson H; Shoshan M; Avall-Lundqvist E
Int J Gynecol Cancer; 2013 Mar; 23(3):448-55. PubMed ID: 23429486
[TBL] [Abstract][Full Text] [Related]
20. [Clinical significance of FOXM1 and Gli-1 protein expression in high-grade ovarian serous carcinoma].
Zhang J; Li ZY; Duan XJ; Fan XM; Liu WN; Li YH
Zhonghua Zhong Liu Za Zhi; 2016 Dec; 38(12):904-908. PubMed ID: 27998466
[No Abstract] [Full Text] [Related]
[Next] [New Search]
